Elevai Labs, Inc. (NASDAQ:ELAB) Short Interest Update

Elevai Labs, Inc. (NASDAQ:ELAB) saw a significant drop in short interest during the month of November. As of November 30th, there was short interest totalling 48,800 shares, a drop of 98.1% from the November 15th total of 2,620,000 shares. Based on an average daily volume of 816,600 shares, the short-interest ratio is presently 0.1 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Elevai Labs stock. Whittier Trust Co. of Nevada Inc. bought a new position in Elevai Labs, Inc. (NASDAQ:ELAB) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 80,666 shares of the company’s stock, valued at approximately $47,000. Whittier Trust Co. of Nevada Inc. owned 0.43% of Elevai Labs at the end of the most recent reporting period. Hedge funds and other institutional investors own 22.22% of the company’s stock.

Elevai Labs Stock Performance

Shares of ELAB traded down $0.15 during mid-day trading on Wednesday, hitting $2.42. The company’s stock had a trading volume of 554,257 shares, compared to its average volume of 229,731. Elevai Labs has a one year low of $1.74 and a one year high of $778.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.40 and a current ratio of 3.86. The firm has a market capitalization of $6.26 million and a PE ratio of -0.04. The stock’s 50-day moving average is $10.39 and its two-hundred day moving average is $59.19.

About Elevai Labs

Elevai Labs, Inc, a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc and changed its name to Elevai Labs, Inc in December 2021.